Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't

Motley Fool2021-09-22

The numbers are in. And they look really good for Moderna, Inc.. On Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（6）

Jrrr92
·2021-09-22
Okie
Reply
2
Report
Winyss10
·2021-09-22
latest
Reply
3
Report
Fold Replies
- Kristo:
  ya
  2021-09-22
  Reply
  Report
AMDidass
·2021-09-22
[鬼臉]
Reply
4
Report
Fold Replies
- AMDidass:
  h
  2021-09-22
  Reply
  Report
StreetMoon
·2021-09-22
Okay ,sell when good news out
Reply
3
Report
D199991D
·2021-09-22
Like
Reply
3
Report
adriandino
·2021-09-22
Buy buy buy
Reply
2
Report
Fold Replies
- doky:
  oh?
  2021-09-22
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2169569506?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-22 17:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2169569506","market":"us","top_or_hot":-1,"title":"Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't","media":"Motley Fool","content":"<div>\n<p>The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 17:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/","article_id":"2169569506","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2169569506","pubTimestamp":1632304440,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"There are a couple of big reasons why Moderna stock isn't as good of a pick as Pfizer right now.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc.","PFE":"辉瑞"},"translate_title":"莫德纳的COVID疫苗可能比辉瑞的好--这就是为什么它的库存不是","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9,"PFE":0.9},"content_text":"The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by Pfizer and BioNTech. Johnson & Johnson's COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.\nThe effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.\nBased on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.\n\nImage source: Getty Images.\nValuation matters\nInvestors who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.\nYou might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.\nIt's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.\nConsider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.\nSo does diversification\nThere's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.\nIn 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.\nWhy is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.\nSure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.\nWhat about growth prospects?\nOne of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.\nModerna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.\nHowever, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has one late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.\nMeanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of Trillium Therapeutics.\nDon't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.\nA tentative advantage\nIt's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.\nBoth Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":869540380,"gmtCreate":1632309095840,"gmtModify":1676530748489,"author":{"id":"3561534918172425","authorId":"3561534918172425","name":"Jrrr92","avatar":"https://static.tigerbbs.com/3713f77c17599af04b8943281769ec65","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3561534918172425","idStr":"3561534918172425"},"htmlText":"Okie","listText":"Okie","text":"Okie","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869540380","repostId":2169569506,"repostType":4,"repost":{"id":"2169569506","pubTimestamp":1632304440,"share":"https://ttm.financial/m/news/2169569506?lang=&edition=fundamental","pubTime":"2021-09-22 17:54","market":"us","language":"en","title":"Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't","url":"https://stock-news.laohu8.com/highlight/detail?id=2169569506","media":"Motley Fool","summary":"There are a couple of big reasons why Moderna stock isn't as good of a pick as Pfizer right now.","content":"<p>The numbers are in. And they look really good for<b> <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b>.</p>\n<p>On Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> and <b>BioNTech</b>. <b>Johnson &amp; Johnson</b>'s&nbsp;COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.</p>\n<p>The effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.</p>\n<p>Based on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.</p>\n<p><img src=\"https://static.tigerbbs.com/becd1618b40219a103b061f6a697c5c6\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Valuation matters</h3>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.</p>\n<p>You might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.</p>\n<p>It's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.</p>\n<p>Consider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.</p>\n<h3>So does diversification</h3>\n<p>There's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.</p>\n<p>In 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.</p>\n<p>Why is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.</p>\n<p>Sure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.</p>\n<h3>What about growth prospects?</h3>\n<p>One of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.</p>\n<p>Moderna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.</p>\n<p>However, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has <a href=\"https://laohu8.com/S/AONE.U\">one</a> late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.</p>\n<p>Meanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of <b><a href=\"https://laohu8.com/S/TRIL\">Trillium Therapeutics</a></b>.</p>\n<p>Don't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.</p>\n<h3>A tentative advantage</h3>\n<p>It's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.</p>\n<p>Both Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 17:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2169569506","content_text":"The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by Pfizer and BioNTech. Johnson & Johnson's COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.\nThe effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.\nBased on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.\n\nImage source: Getty Images.\nValuation matters\nInvestors who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.\nYou might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.\nIt's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.\nConsider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.\nSo does diversification\nThere's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.\nIn 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.\nWhy is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.\nSure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.\nWhat about growth prospects?\nOne of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.\nModerna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.\nHowever, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has one late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.\nMeanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of Trillium Therapeutics.\nDon't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.\nA tentative advantage\nIt's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.\nBoth Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":869523586,"gmtCreate":1632306691445,"gmtModify":1676530748016,"author":{"id":"3576987369058453","authorId":"3576987369058453","name":"Winyss10","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3576987369058453","idStr":"3576987369058453"},"htmlText":"latest","listText":"latest","text":"latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869523586","repostId":2169569506,"repostType":4,"repost":{"id":"2169569506","pubTimestamp":1632304440,"share":"https://ttm.financial/m/news/2169569506?lang=&edition=fundamental","pubTime":"2021-09-22 17:54","market":"us","language":"en","title":"Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't","url":"https://stock-news.laohu8.com/highlight/detail?id=2169569506","media":"Motley Fool","summary":"There are a couple of big reasons why Moderna stock isn't as good of a pick as Pfizer right now.","content":"<p>The numbers are in. And they look really good for<b> <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b>.</p>\n<p>On Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> and <b>BioNTech</b>. <b>Johnson &amp; Johnson</b>'s&nbsp;COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.</p>\n<p>The effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.</p>\n<p>Based on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.</p>\n<p><img src=\"https://static.tigerbbs.com/becd1618b40219a103b061f6a697c5c6\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Valuation matters</h3>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.</p>\n<p>You might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.</p>\n<p>It's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.</p>\n<p>Consider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.</p>\n<h3>So does diversification</h3>\n<p>There's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.</p>\n<p>In 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.</p>\n<p>Why is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.</p>\n<p>Sure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.</p>\n<h3>What about growth prospects?</h3>\n<p>One of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.</p>\n<p>Moderna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.</p>\n<p>However, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has <a href=\"https://laohu8.com/S/AONE.U\">one</a> late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.</p>\n<p>Meanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of <b><a href=\"https://laohu8.com/S/TRIL\">Trillium Therapeutics</a></b>.</p>\n<p>Don't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.</p>\n<h3>A tentative advantage</h3>\n<p>It's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.</p>\n<p>Both Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 17:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2169569506","content_text":"The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by Pfizer and BioNTech. Johnson & Johnson's COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.\nThe effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.\nBased on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.\n\nImage source: Getty Images.\nValuation matters\nInvestors who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.\nYou might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.\nIt's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.\nConsider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.\nSo does diversification\nThere's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.\nIn 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.\nWhy is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.\nSure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.\nWhat about growth prospects?\nOne of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.\nModerna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.\nHowever, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has one late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.\nMeanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of Trillium Therapeutics.\nDon't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.\nA tentative advantage\nIt's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.\nBoth Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5958310,"gmtCreate":1632307053920,"gmtModify":1663234270148,"authorId":3557634928383187,"author":{"id":3557634928383187,"idStr":"3557634928383187","authorId":3557634928383187,"name":"Kristo","avatar":"https://static.tigerbbs.com/07075676425d47f31685477722d0d415","vip":1,"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":869523586,"type":1,"supId":0,"prevId":0,"content":"ya","text":"ya","html":"ya"}],"langContent":"EN"},{"id":869564600,"gmtCreate":1632306044000,"gmtModify":1676530747928,"author":{"id":"3581594133816177","authorId":"3581594133816177","name":"AMDidass","avatar":"https://community-static.tradeup.com/news/2ecf5d1a5d472aa9dd7520e347659635","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3581594133816177","idStr":"3581594133816177"},"htmlText":"[鬼臉]&nbsp;","listText":"[鬼臉]&nbsp;","text":"[鬼臉]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869564600","repostId":2169569506,"repostType":4,"repost":{"id":"2169569506","pubTimestamp":1632304440,"share":"https://ttm.financial/m/news/2169569506?lang=&edition=fundamental","pubTime":"2021-09-22 17:54","market":"us","language":"en","title":"Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't","url":"https://stock-news.laohu8.com/highlight/detail?id=2169569506","media":"Motley Fool","summary":"There are a couple of big reasons why Moderna stock isn't as good of a pick as Pfizer right now.","content":"<p>The numbers are in. And they look really good for<b> <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b>.</p>\n<p>On Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> and <b>BioNTech</b>. <b>Johnson &amp; Johnson</b>'s&nbsp;COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.</p>\n<p>The effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.</p>\n<p>Based on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.</p>\n<p><img src=\"https://static.tigerbbs.com/becd1618b40219a103b061f6a697c5c6\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Valuation matters</h3>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.</p>\n<p>You might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.</p>\n<p>It's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.</p>\n<p>Consider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.</p>\n<h3>So does diversification</h3>\n<p>There's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.</p>\n<p>In 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.</p>\n<p>Why is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.</p>\n<p>Sure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.</p>\n<h3>What about growth prospects?</h3>\n<p>One of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.</p>\n<p>Moderna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.</p>\n<p>However, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has <a href=\"https://laohu8.com/S/AONE.U\">one</a> late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.</p>\n<p>Meanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of <b><a href=\"https://laohu8.com/S/TRIL\">Trillium Therapeutics</a></b>.</p>\n<p>Don't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.</p>\n<h3>A tentative advantage</h3>\n<p>It's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.</p>\n<p>Both Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 17:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2169569506","content_text":"The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by Pfizer and BioNTech. Johnson & Johnson's COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.\nThe effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.\nBased on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.\n\nImage source: Getty Images.\nValuation matters\nInvestors who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.\nYou might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.\nIt's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.\nConsider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.\nSo does diversification\nThere's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.\nIn 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.\nWhy is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.\nSure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.\nWhat about growth prospects?\nOne of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.\nModerna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.\nHowever, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has one late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.\nMeanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of Trillium Therapeutics.\nDon't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.\nA tentative advantage\nIt's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.\nBoth Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5958176,"gmtCreate":1632306076712,"gmtModify":1663234268929,"authorId":3581594133816177,"author":{"id":3581594133816177,"idStr":"3581594133816177","authorId":3581594133816177,"name":"AMDidass","avatar":"https://community-static.tradeup.com/news/2ecf5d1a5d472aa9dd7520e347659635","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Have published 3 or more picked posts, and have published at least one picked post and participated in comments within 30 days","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":0,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.31","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"},"individualDisplaySort":0,"categoryType":2007}]},"repliedAuthorId":0,"objectId":869564600,"type":1,"supId":0,"prevId":0,"content":"<u>h</u>","text":"<u>h</u>","html":"<u>h</u>"}],"langContent":"CN"},{"id":869564999,"gmtCreate":1632305944711,"gmtModify":1676530747920,"author":{"id":"3581450937859419","authorId":"3581450937859419","name":"StreetMoon","avatar":"https://static.tigerbbs.com/66309fcb0dabf3ca68ead8e251963340","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3581450937859419","idStr":"3581450937859419"},"htmlText":"Okay ,sell when good news out&nbsp;","listText":"Okay ,sell when good news out&nbsp;","text":"Okay ,sell when good news out","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869564999","repostId":2169569506,"repostType":4,"repost":{"id":"2169569506","pubTimestamp":1632304440,"share":"https://ttm.financial/m/news/2169569506?lang=&edition=fundamental","pubTime":"2021-09-22 17:54","market":"us","language":"en","title":"Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't","url":"https://stock-news.laohu8.com/highlight/detail?id=2169569506","media":"Motley Fool","summary":"There are a couple of big reasons why Moderna stock isn't as good of a pick as Pfizer right now.","content":"<p>The numbers are in. And they look really good for<b> <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b>.</p>\n<p>On Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> and <b>BioNTech</b>. <b>Johnson &amp; Johnson</b>'s&nbsp;COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.</p>\n<p>The effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.</p>\n<p>Based on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.</p>\n<p><img src=\"https://static.tigerbbs.com/becd1618b40219a103b061f6a697c5c6\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Valuation matters</h3>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.</p>\n<p>You might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.</p>\n<p>It's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.</p>\n<p>Consider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.</p>\n<h3>So does diversification</h3>\n<p>There's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.</p>\n<p>In 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.</p>\n<p>Why is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.</p>\n<p>Sure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.</p>\n<h3>What about growth prospects?</h3>\n<p>One of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.</p>\n<p>Moderna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.</p>\n<p>However, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has <a href=\"https://laohu8.com/S/AONE.U\">one</a> late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.</p>\n<p>Meanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of <b><a href=\"https://laohu8.com/S/TRIL\">Trillium Therapeutics</a></b>.</p>\n<p>Don't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.</p>\n<h3>A tentative advantage</h3>\n<p>It's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.</p>\n<p>Both Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 17:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2169569506","content_text":"The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by Pfizer and BioNTech. Johnson & Johnson's COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.\nThe effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.\nBased on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.\n\nImage source: Getty Images.\nValuation matters\nInvestors who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.\nYou might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.\nIt's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.\nConsider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.\nSo does diversification\nThere's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.\nIn 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.\nWhy is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.\nSure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.\nWhat about growth prospects?\nOne of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.\nModerna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.\nHowever, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has one late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.\nMeanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of Trillium Therapeutics.\nDon't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.\nA tentative advantage\nIt's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.\nBoth Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":869568537,"gmtCreate":1632305354529,"gmtModify":1676530747832,"author":{"id":"3577352301253695","authorId":"3577352301253695","name":"D199991D","avatar":"https://static.tigerbbs.com/49e24e0e3faeb8d389ad5d2db8a0e240","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3577352301253695","idStr":"3577352301253695"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869568537","repostId":2169569506,"repostType":4,"repost":{"id":"2169569506","pubTimestamp":1632304440,"share":"https://ttm.financial/m/news/2169569506?lang=&edition=fundamental","pubTime":"2021-09-22 17:54","market":"us","language":"en","title":"Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't","url":"https://stock-news.laohu8.com/highlight/detail?id=2169569506","media":"Motley Fool","summary":"There are a couple of big reasons why Moderna stock isn't as good of a pick as Pfizer right now.","content":"<p>The numbers are in. And they look really good for<b> <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b>.</p>\n<p>On Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> and <b>BioNTech</b>. <b>Johnson &amp; Johnson</b>'s&nbsp;COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.</p>\n<p>The effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.</p>\n<p>Based on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.</p>\n<p><img src=\"https://static.tigerbbs.com/becd1618b40219a103b061f6a697c5c6\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Valuation matters</h3>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.</p>\n<p>You might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.</p>\n<p>It's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.</p>\n<p>Consider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.</p>\n<h3>So does diversification</h3>\n<p>There's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.</p>\n<p>In 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.</p>\n<p>Why is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.</p>\n<p>Sure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.</p>\n<h3>What about growth prospects?</h3>\n<p>One of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.</p>\n<p>Moderna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.</p>\n<p>However, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has <a href=\"https://laohu8.com/S/AONE.U\">one</a> late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.</p>\n<p>Meanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of <b><a href=\"https://laohu8.com/S/TRIL\">Trillium Therapeutics</a></b>.</p>\n<p>Don't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.</p>\n<h3>A tentative advantage</h3>\n<p>It's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.</p>\n<p>Both Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 17:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2169569506","content_text":"The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by Pfizer and BioNTech. Johnson & Johnson's COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.\nThe effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.\nBased on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.\n\nImage source: Getty Images.\nValuation matters\nInvestors who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.\nYou might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.\nIt's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.\nConsider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.\nSo does diversification\nThere's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.\nIn 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.\nWhy is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.\nSure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.\nWhat about growth prospects?\nOne of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.\nModerna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.\nHowever, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has one late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.\nMeanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of Trillium Therapeutics.\nDon't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.\nA tentative advantage\nIt's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.\nBoth Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":869568971,"gmtCreate":1632305103093,"gmtModify":1676530747819,"author":{"id":"3557838603033373","authorId":"3557838603033373","name":"adriandino","avatar":"https://static.tigerbbs.com/7ee1cd14ed5057e0ad135ec52ba710cf","vip":1,"crmLevel":4,"crmLevelSwitch":1,"authorIdStr":"3557838603033373","idStr":"3557838603033373"},"htmlText":"Buy buy buy&nbsp;","listText":"Buy buy buy&nbsp;","text":"Buy buy buy","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869568971","repostId":2169569506,"repostType":4,"repost":{"id":"2169569506","pubTimestamp":1632304440,"share":"https://ttm.financial/m/news/2169569506?lang=&edition=fundamental","pubTime":"2021-09-22 17:54","market":"us","language":"en","title":"Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't","url":"https://stock-news.laohu8.com/highlight/detail?id=2169569506","media":"Motley Fool","summary":"There are a couple of big reasons why Moderna stock isn't as good of a pick as Pfizer right now.","content":"<p>The numbers are in. And they look really good for<b> <a href=\"https://laohu8.com/S/MRNA\">Moderna, Inc.</a></b>.</p>\n<p>On Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by <b><a href=\"https://laohu8.com/S/PFE\">Pfizer</a></b> and <b>BioNTech</b>. <b>Johnson &amp; Johnson</b>'s&nbsp;COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.</p>\n<p>The effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.</p>\n<p>Based on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.</p>\n<p><img src=\"https://static.tigerbbs.com/becd1618b40219a103b061f6a697c5c6\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: <a href=\"https://laohu8.com/S/GTY\">Getty</a> Images.</p>\n<h3>Valuation matters</h3>\n<p><a href=\"https://laohu8.com/S/ISBC\">Investors</a> who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.</p>\n<p>You might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.</p>\n<p>It's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.</p>\n<p>Consider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.</p>\n<h3>So does diversification</h3>\n<p>There's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.</p>\n<p>In 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.</p>\n<p>Why is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.</p>\n<p>Sure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.</p>\n<h3>What about growth prospects?</h3>\n<p>One of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.</p>\n<p>Moderna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.</p>\n<p>However, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has <a href=\"https://laohu8.com/S/AONE.U\">one</a> late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.</p>\n<p>Meanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of <b><a href=\"https://laohu8.com/S/TRIL\">Trillium Therapeutics</a></b>.</p>\n<p>Don't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.</p>\n<h3>A tentative advantage</h3>\n<p>It's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.</p>\n<p>Both Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn't\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 17:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/22/modernas-covid-vaccine-could-be-better-than-pfizer/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2169569506","content_text":"The numbers are in. And they look really good for Moderna, Inc..\nOn Sept. 17, the Centers for Disease Control and Prevention (CDC) released interim data that compared the effectiveness of the three COVID-19 vaccines on the market in the U.S. Moderna's vaccine was found to be 93% effective at preventing hospitalizations, compared to 88% for the vaccine developed by Pfizer and BioNTech. Johnson & Johnson's COVID-19 vaccine trailed behind both with an effectiveness against hospitalization of 71%.\nThe effectiveness of Moderna's and Pfizer's vaccines was very close in preventing infection during the first few months after the second dose -- 92% and 91%, respectively. However, after 120 days, the effectiveness for Moderna's vaccine slipped only 1%, while Pfizer's vaccine effectiveness declined by 14%.\nBased on the CDC data, Moderna's COVID-19 vaccine appears to be better than Pfizer's vaccine. But here's why its stock isn't.\n\nImage source: Getty Images.\nValuation matters\nInvestors who buy growth stocks sometimes believe that valuation is irrelevant. That's not the case, though. Valuation always matters. However, sometimes traditional valuation metrics don't apply very well to especially fast-growing stocks.\nYou might think that Moderna and Pfizer stack up relatively closely if you only looked at their forward earnings multiples. Moderna's shares trade at a little over 14 times expected earnings, while Pfizer stock trades at a little over 12 times expected earnings.\nIt's a much different story examining the two price-to-sales (P/S) multiples of the two vaccine stocks, though. Moderna's shares trade at more than 25 times sales. Pfizer's P/S multiple is less than 4.5.\nConsider that Wall Street's consensus price target for Moderna is 26% below its current price. Meanwhile, the average analysts' price target for Pfizer reflects a modest 4% premium above the current share price. Why are views so different for these two stocks? Valuation. Analysts recognize that Moderna is priced at a nosebleed level, but Pfizer isn't.\nSo does diversification\nThere's arguably an even more important reason why Pfizer is a better stock to buy than Moderna, though. Moderna's near-term fortunes hinge solely on sales of its COVID-19 vaccine. Although Pfizer's Comirnaty vaccine is its top-selling product, the company has a much more diversified revenue base.\nIn 2020, Pfizer's lineup included seven blockbuster products plus a long list of other drugs with sales in the hundreds of millions of dollars. The company was already poised to deliver solid growth even without its COVID-19 vaccine.\nWhy is Pfizer's diversification advantage over Moderna so important? There's considerable uncertainty about the dynamics of the COVID-19 vaccine market after next year. Both of these companies could experience sales declines for their COVID-19 vaccines once the pandemic ends.\nSure, there's a good chance that COVID-19 vaccines will be needed on a regular basis, perhaps annually, over the long term. However, the sales levels projected for 2021 and 2022 might not be sustainable even in this scenario.\nWhat about growth prospects?\nOne of the top reasons why many investors like Moderna is its growth prospects. The idea is that the company will be able to revolutionize how viruses are prevented and how other diseases are treated with its messenger RNA (mRNA) platform.\nModerna could very well be able to launch multiple mRNA vaccines and therapies over the next decade and beyond, driving tremendous growth. There's even a path for the stock to double despite having a steep valuation right now.\nHowever, everything has to go right for Moderna. And it will take years for the company's pipeline programs to progress through clinical testing and hopefully win regulatory approval. Outside of its COVID-19 vaccine, Moderna only has one late-stage candidate. And that's being generous since its cytomegalovirus vaccine doesn't advance into phase 3 testing until later this year.\nMeanwhile, Pfizer's pipeline includes 23 late-stage programs. This count excludes a handful of candidates already awaiting regulatory approval. Pfizer's pipeline should also be bolstered in the near future with its pending acquisition of Trillium Therapeutics.\nDon't think that Moderna has the mRNA arena all to itself, either. Pfizer and BioNTech are working together on an mRNA flu vaccine. Pfizer has also committed to moving forward with developing mRNA vaccines and therapies on its own.\nA tentative advantage\nIt's possible that Moderna's effectiveness advantage could have a downside. A U.S. Food and Drug Administration (FDA) advisory committee has already opted to only recommend boosters of the Pfizer-BioNTech vaccine for ages 65 and up and for individuals with high risk because of sustained efficacy of the vaccine against preventing severe COVID-19. Moderna's even greater effectiveness could reduce the odds that boosters for its vaccine are authorized.\nBoth Pfizer and Moderna are also developing new vaccines that specifically target emerging variants. Any advantage that Moderna enjoys currently could only be temporary. On the other hand, the advantages that Pfizer stock has over Moderna will likely remain in place longer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5958532,"gmtCreate":1632309026622,"gmtModify":1663234270249,"authorId":3567308634822078,"author":{"id":3567308634822078,"idStr":"3567308634822078","authorId":3567308634822078,"name":"doky","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":869568971,"type":1,"supId":0,"prevId":0,"content":"oh?","text":"oh?","html":"oh?"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":58,"commentSize":6,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}